| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $9.7M | — | -15.9% |
| SG&A Expense | $6.4M | — | -12.2% |
| Income Tax | $0 | — | — |
| Net Income | -$14.7M | — | +11.5% |
| EPS (Basic) | -$0.12 | — | +7.7% |
| EPS (Diluted) | -$0.12 | — | +7.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $14.6M | +18.1% | -56.0% |
| Inventory | $300K | — | — |
| Current Assets | $98.8M | -6.7% | -30.2% |
| Total Assets | $177.8M | -7.0% | -21.9% |
| Current Liabilities | $8.3M | +4.9% | +2.3% |
| Total Liabilities | $33.4M | -2.3% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$13.1M | — | +6.0% |
| Capital Expenditures | $510K | — | +132.9% |
| Investing Cash Flow | $14.2M | — | -27.1% |
| Financing Cash Flow | $1.1M | — | +6038.9% |
| Free Cash Flow | -$13.6M | — | +3.9% |
| +0.3% |
| Stockholders' Equity | $144.4M | -8.0% | -25.7% |